Naval Daver, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses frontline approaches for patients with FLT3-mutated acute myeloid leukemia (AML), including quizartinib with intensive chemotherapy, based on data from the Phase III QuANTUM-First trial (NCT02668653). Dr Daver also highlights high remission rates and improved survival in trials of lower-intensity triplet combination regimens consisting of a hypomethylating agent, venetoclax, and gilteritinib (NCT04140487) or quizartinib (NCT03661307), and notes RAS mutations as a key resistance mechanism. This presentation took place at the 8th International Workshop on Acute Leukemias (iwAL) 2026, held in Cambridge, MA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.